Almost two-thirds of patients in the UK would consider paying for diagnostics out of pocket if they face a long wait for free NHS testing, and almost all want to see more
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh